{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"16"},{"groupId":"OG001","value":"16"}]}],"title":"Month 9"},{"categories":[{"measurements":[{"groupId":"OG000","value":"13"},{"groupId":"OG001","value":"12"}]}],"title":"Month 18"}],"denoms":[{"counts":[{"groupId":"OG000","value":"122"},{"groupId":"OG001","value":"121"}],"units":"Participants"}],"description":"CR was defined as:\n\n* Absence of the original monoclonal paraprotein in serum and urine by immunofixation, maintained for a minimum of 6 weeks;\n* \\<5% plasma cells in a bone marrow aspirate and also on trephine bone biopsy, if biopsy was performed.\n* No increase in size or number of lytic bone lesions (development of a compression fracture did not include response);\n* Disappearance of soft tissue plasmocytomas.","groups":[{"description":"Peginterferon α-2b 35 μg, weekly, subcutaneous (SC), until disease progression or relapse, or for up to a maximum of 5 years.","id":"OG000","title":"Peginterferon α-2b"},{"description":"Participants were observed and received no treatment","id":"OG001","title":"No Treatment"}],"paramType":"NUMBER","populationDescription":"Intent-to-treat population (those who received at least one dose of study drug)","reportingStatus":"POSTED","timeFrame":"Month 9 & Month 18","title":"Number of Participants With Complete Response (CR) to Treatment","type":"SECONDARY","unitOfMeasure":"Participants"}